Clinical Trials Browser

OTHER × lorlatinib × 30 days × Clear all

NCT07415005 2026-05-05

Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

Phase 2 Recruiting

Advanced Non-Small Cell Lung Cancer